electroCore FY2025 net sales rise 27% to USD 32.03 million as GAAP net loss widens to USD 13.97 million

Reuters
Mar 20
electroCore FY2025 net sales rise 27% to USD 32.03 million as GAAP net loss widens to USD 13.97 million
  • electroCore published a press release reporting full-year financial results, with net sales of USD 32.03 million, up 27%, driven by 25% growth in U.S. prescription sales and a 97% increase in general wellness sales.
  • Gross profit was USD 27.79 million and gross margin was 87%, up 2 percentage points.
  • GAAP net loss was USD 13.97 million and adjusted EBITDA net loss was USD 8.69 million.
  • Total cash (cash, cash equivalents, and marketable securities) was USD 11.6 million at Dec. 31, 2025.
  • The company guided for about 30% revenue growth in 2026 and said CEO Dan Goldberger will retire effective April 1, 2026, with Joshua Lev becoming interim President alongside his CFO role and Michael Fox joining as COO.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. electroCore Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603191605PRIMZONEFULLFEED9675270) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10